356 related articles for article (PubMed ID: 33086429)
41. The Effect of a Cardiovascular Polypill Strategy on Pill Burden.
Truelove M; Patel A; Bompoint S; Brown A; Cass A; Hillis GS; Peiris D; Rafter N; Reid CM; Rodgers A; Tonkin A; Usherwood T; Webster R;
Cardiovasc Ther; 2015 Dec; 33(6):347-52. PubMed ID: 26280247
[TBL] [Abstract][Full Text] [Related]
42. Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Muñoz D; Uzoije P; Reynolds C; Miller R; Walkley D; Pappalardo S; Tousey P; Munro H; Gonzales H; Song W; White C; Blot WJ; Wang TJ
N Engl J Med; 2019 Sep; 381(12):1114-1123. PubMed ID: 31532959
[TBL] [Abstract][Full Text] [Related]
43. The polypill: a potential global solution to cardiovascular disease.
Nguyen C; Cheng-Lai A
Cardiol Rev; 2013; 21(1):49-54. PubMed ID: 23018668
[TBL] [Abstract][Full Text] [Related]
44. Effect of the Polypill on Adherence and Prevention of Cardiovascular Diseases in Patients With or at High Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials.
Memon RA; Raveena Bai B; Simran F; Kumari M; Aisha F; Sai Kiran K; Kakarlapudi Y; Saleem F
Cureus; 2023 Jan; 15(1):e34134. PubMed ID: 36843692
[TBL] [Abstract][Full Text] [Related]
45. Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease.
Wood F; Salam A; Singh K; Day S; Jan S; Prabhakaran D; Rodgers A; Patel A; Thom S; Ward H
BMJ Open; 2015 Sep; 5(9):e008018. PubMed ID: 26423850
[TBL] [Abstract][Full Text] [Related]
46. Can a polypill one single tablet combat different cardiovascular risk factors?
Rosenthal T
J Am Soc Hypertens; 2018 May; 12(5):335-339. PubMed ID: 29573975
[TBL] [Abstract][Full Text] [Related]
47. Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges.
; Yusuf S; Attaran A; Bosch J; Joseph P; Lonn E; McCready T; Mente A; Nieuwlaat R; Pais P; Rodgers A; Schwalm JD; Smith R; Teo K; Xavier D
Eur Heart J; 2014 Feb; 35(6):353-64. PubMed ID: 24288261
[TBL] [Abstract][Full Text] [Related]
48. A practical approach to switch from a multiple pill therapeutic strategy to a polypill-based strategy for cardiovascular prevention in patients with hypertension.
Coca A; Kreutz R; Manolis AJ; Mancia G
J Hypertens; 2020 Oct; 38(10):1890-1898. PubMed ID: 32890261
[TBL] [Abstract][Full Text] [Related]
49. A protocol for an economic evaluation of a polypill in patients with established or at high risk of cardiovascular disease in a UK NHS setting: RUPEE (NHS) study.
Crossan C; Dehbi HM; Williams H; Poulter N; Rodgers A; Jan S; Thom S; Lord J
BMJ Open; 2018 Mar; 8(3):e013063. PubMed ID: 29540403
[TBL] [Abstract][Full Text] [Related]
50. Effectiveness of Polypill for Prevention of Cardiovascular Disease (PolyPars): Protocol of a Randomized Controlled Trial.
Malekzadeh F; Gandomkar A; Malekzadeh Z; Poustchi H; Moghadami M; Fattahi MR; Moini M; Anushiravani A; Mortazavi R; Sadeghi Boogar S; Mohammadkarimi V; Abtahi F; Merat S; Sepanlou SG; Malekzadeh R
Arch Iran Med; 2020 Aug; 23(8):548-556. PubMed ID: 32894967
[TBL] [Abstract][Full Text] [Related]
51. Impact of switching to polypill based therapy by baseline potency of medication: Post-hoc analysis of the SPACE Collaboration dataset.
Webster R; Bullen C; Patel A; Selak V; Stepien S; Thom S; Rodgers A
Int J Cardiol; 2017 Dec; 249():443-447. PubMed ID: 28986058
[TBL] [Abstract][Full Text] [Related]
52. [Management of different cardiovascular risk factors with a combination tablet (polypill)].
Bramlage P; März W; Westermann D; Weisser B; Wirtz JH; Zeymer U; Baumgart P; van Mark G; Laufs U; Krämer BK; Unger T
Herz; 2018 May; 43(3):246-257. PubMed ID: 28341983
[TBL] [Abstract][Full Text] [Related]
53. A polypill strategy to improve adherence: results from the FOCUS project.
Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
[TBL] [Abstract][Full Text] [Related]
54. The cardiovascular polypill in high-risk patients.
Lafeber M; Spiering W; Singh K; Guggilla RK; Patil V; Webster R;
Eur J Prev Cardiol; 2012 Dec; 19(6):1234-42. PubMed ID: 22019908
[TBL] [Abstract][Full Text] [Related]
55. Uses of polypills for cardiovascular disease and evidence to date.
Huffman MD; Xavier D; Perel P
Lancet; 2017 Mar; 389(10073):1055-1065. PubMed ID: 28290995
[TBL] [Abstract][Full Text] [Related]
56. Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials.
Selak V; Webster R; Stepien S; Bullen C; Patel A; Thom S; Arroll B; Bots ML; Brown A; Crengle S; Dorairaj P; Elley CR; Grobbee DE; Harwood M; Hillis GS; Laba TL; Neal B; Peiris D; Rafter N; Reid C; Stanton A; Tonkin A; Usherwood T; Wadham A; Rodgers A
Heart; 2019 Jan; 105(1):42-48. PubMed ID: 29954855
[TBL] [Abstract][Full Text] [Related]
57. Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease.
Selak V; Bullen C; Stepien S; Arroll B; Bots M; Bramley D; Cass A; Grobbee D; Hillis GS; Molanus B; Neal B; Patel A; Rafter N; Rodgers A; Thom S; Tonkin A; Usherwood T; Wadham A; Webster R
Eur J Prev Cardiol; 2016 Sep; 23(13):1393-400. PubMed ID: 26945024
[TBL] [Abstract][Full Text] [Related]
58. Polypill Trials for Stroke Prevention-Main Results, Critical Appraisal, and Implications for US Population.
Ibraheem M; Goldstein LB
Curr Neurol Neurosci Rep; 2020 Apr; 20(5):10. PubMed ID: 32296941
[TBL] [Abstract][Full Text] [Related]
59. Combined use of polypill components in patients with type 2 diabetes mellitus.
Janssen VE; Visseren FL; de Boer A; Grobbee DE; Westerink J; van der Graaf Y; Lafeber M;
Eur J Prev Cardiol; 2018 Sep; 25(14):1523-1531. PubMed ID: 30033753
[TBL] [Abstract][Full Text] [Related]
60. Polypills for the prevention of Cardiovascular diseases.
Kolte D; Aronow WS; Banach M
Expert Opin Investig Drugs; 2016 Nov; 25(11):1255-1264. PubMed ID: 27645895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
